GKOS - Multiplikator Forward P/S Glaukos Corp.

The expected revenue multiple demonstrates the business valuation dynamics, where 21.10 shows the value of this parameter. Glaukos Corporation (GKOS) is implementing minimally invasive glaucoma treatments, replacing conventional therapy. High margins are driven by the production of low-cost titanium chips following expensive R&D. The global expansion of microstent application creates powerful operating leverage, effectively offsetting research and development costs.

Assessing the financial stability of Glaukos Corporation (GKOS) requires an analysis of the balance between market value and expected revenue, taking into account the high cost of express implant delivery. The forward P/S trend reflects the supply-demand ratio relative to future earnings, where the chart's volatility signals the speculative nature of the business valuation and the risks of temporary investment capital lock-up.